• About
• Links
• Contact
• Sitemap

The Global Antivirals Market

 

Overview

The global anti-infective market is currently valued at US$66.5 billion with antiviral agents accounting for 24% of sales (excluding vaccines which target viral infectious diseases).

According to The Antivirals Market: R&D Pipelines, Markey Analysis and Competitive Landscape, the anti-viral market will be driven by the uptake of newer anti-retroviral agents in combination therapy and the launch of ten new products for the treatment of HIV and hepatitis which will address the need of treatment-resistant patients. This will help to stem the tide of this prevalent and often lethal killer in our society today.

Pharmaceutical companies continue to develop a new generation of antiretroviral agents to overcome the issue of drug and cross-resistance. Meanwhile new drug classes are under evaluation that increases the virologists armory against these endemic and often deadly infectious diseases.

This report examines each of the antiviral classes in turn, assessing the market potential and encompassing the major infectious diseases to which they are applicable.

The following product classes are analyzed in this report:

• antisense
• attachment, entry and fusion inhibitors
• DNA polymerase inhibitors
• integrase inhibitors
• interferons
• maturation inhibitors
• monoclonal antibodies
• neuraminidase inhibitors
• NS3 protease inhibitors
• nucleoside reverse transcriptase inhibitors
• nucleotide reverse transcriptase inhibitors
• protease inhibitors
• reverse transcriptase inhibitors
• RNA polymerase inhibitors

The report assesses the overall antiviral market, key classes, the drivers and resistors influencing their prescription. The report provides an overview of key products in each category, summarizing their clinical efficacy and marketing position. The overview of the current market is given in terms of segmentation by category and by leading players, therapies and their products and analyzes market trends.

The report examines promising pipeline products and their potential impact on the prescription of current and new antiviral agents and the future antiviral market.

Key features of this report:

• Overview of the antiviral market, including main infectious agents, therapeutic drug classes and key players.

• In-depth analysis of different classes of antiviral agents, including key antiretroviral and antiviral agents and compares drugs within each class.

• Comprehensive facts and figures for the antiviral market, including main players and therapeutic break-downs.

• Future trends in the antiviral marketplace, driven by drug resistance, cross-resistance and patient demographics.

• Outlook for the antiviral market, including the emergence of novel therapies, new combination therapies and the impact of generics.

---

Table of Contents

• Table of Contents
•  
  • 1EXECUTIVE SUMMARY
  • 2INTRODUCTION TO INFECTIOUS DISEASES
    • 2.1Cytomegalovirus (CMV)
    • 2.2Hepatitis B virus (HBV)
    • 2.3Hepatitis C Virus (HCV)
    • 2.4Herpes Simplex Virus (HSV)
    • 2.5Human Immunodeficiency Virus (HIV)
    • 2.6Influenza (Flu)
    • 2.7Respiratory Syncytial Virus (RSV)
  • 3PATIENT DEMOGRAPHICS
    • 3.1Cytomegalovirus Patient Statistics
    • 3.2Hepatitis B Patient Statistics
    • 3.3Hepatitis C Patient Statistics
    • 3.4Herpes Simplex Patient Statistics
    • 3.5Human Immunodeficiency Patient Statistics
    • 3.6Influenza Patient Statistics
    • 3.7Respiratory Syncytial Patient Statistics
  • 4KEY DRIVERS
    • 4.1Drug Resistance
    • 4.2Cross-Resistance
    • 4.3New treatments
    • 4.4Combination therapy
    • 4.5Improvements in diagnosis
    • 4.6Vaccines
    • 4.7Potential for clinical success
    • 4.8Indirect cost associated with infectious diseases
  • 5KEY RESISTORS
    • 5.1Cost-benefit of prophylactic therapy or antiviral therapy
    • 5.2Treatment availability
    • 5.3Patient demographics
    • 5.4Generics
    • 5.5Curative Therapies and Vaccines
    • 5.6Diagnosis
  • 6THE MARKET
    • 6.1The Global Anti-Infective Market
    • 6.2Market Segments
    • 6.3Global Anti-Viral Market
      • 6.3.1Antiretroviral Agents
      • 6.3.2Hepatitis Antiviral Agents
      • 6.3.3Other Antiviral Agents
    • 6.4The Major Players
      • 6.4.1Antiviral Major Players in 2006
      • 6.4.2Antiviral Major Players in 2012
    • 6.5Market Trends
      • 6.5.1Antiretroviral Agents by 2012
      • 6.5.2Hepatitis Agents by 2012
      • 6.5.3Other Antiviral Agents by 2012
  • 7LEADING DRUG CLASSES
    • 7.1Antisense
    • 7.2DNA Polymerase Inhibitors
    • 7.3Interferons
    • 7.4Fusion Inhibitors
    • 7.5Neuraminidase Inhibitors
    • 7.6Reverse Transcriptase Inhibitors
    • 7.7RNA Polymerase Inhibitors
    • 7.8Protease Inhibitors
    • 7.9Uncoating Inhibitors
  • 8LEADING BRANDS
    • 8.1Antisense
      • 8.1.1Vitravene (Novartis/[ISIS Pharmaceuticals])
      • 8.1.2Antisense Sales Forecasts
    • 8.2DNA Polymerase Inhibitors
      • 8.2.1DNA Polymerase Inhibitors Forecasts
    • 8.3RNA Polymerase Inhibitors
      • 8.3.1RNA Polymerase Inhibitors Forecasts
    • 8.4Fusion Inhibitors
      • 8.4.1Fuzeon (Roche/Trimeris)
        • 8.4.1.1Fuzeon’s tolerability profile
        • 8.4.1.2Fuzeon’s Needle-Free Device
      • 8.4.2Fusion Inhibitor Sales Forecasts
    • 8.5Inteferons
      • 8.5.1Interferon Sales Forecasts
    • 8.6Monoclonal Antibodies
      • 8.6.1Synagis (MedImmune)
      • 8.6.2Monoclonal Antibody Sales Forecasts
    • 8.7Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
      • 8.7.1NNRTI Sales Forecasts
    • 8.8Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      • 8.8.1NRTIs Combination Franchises
      • 8.8.2NRTI Sales Forecasts
    • 8.9Nucleotide Reverse Transcriptase Inhibitors (NtRTIs)
      • 8.9.1NtRTI Sales Forecasts
    • 8.10Protease Inhibitors
      • 8.10.1PI Sales Forecasts
    • 8.11Neuraminidase Inhibitors (NIs)
      • 8.11.1Neuraminidase Inhibitors Sales Forecasts
    • 8.12Global Anti-Viral Sales Forecasts
  • 9FUTURE BRANDS
    • 9.1Attachment, Entry and Fusion Inhibitors
      • 9.1.1AMD070 (AnorMed/Genzyme)
      • 9.1.2BMS-488043 (Bristol-Myers Squibb)
      • 9.1.3FP-21399 (EMD Lexigen)
      • 9.1.4HIV Fusion Inhibitor (Panacos)
      • 9.1.5Maraviroc (Pfizer)
    • 9.1.Ongoing pivotal Phase II/III Maraviroc trails
      • 9.1.6PRO 140 (Progenics)
      • 9.1.7SP01A (Samaritan Pharmaceuticals)
      • 9.1.8TNX-355 (Tanox/Biogen Idec)
      • 9.1.9T-1249 / TRI-1144/TRI-999 (Roche/Trimeris)
      • 9.1.10Vicriviroc (Schering-Plough)
    • 9.1.Safety Profile of Vicriviroc
    • 9.2Integrase Inhibitors
      • 9.2.1GS 9137 (Gilead Sciences/[Japan Tobacco])
      • 9.2.2MK-0518 (Merck & Co)
        • 9.2.2.1Safety Profile of MK-0518
    • 9.3Interferons
      • 9.3.1Albuferon (Novartis/Human Genome Sciences)
        • 9.3.1.1Pivotal ACHIEVE Trial results
    • 9.4Maturation Inhibitors
      • 9.4.1Bevirimat (Panacos)
        • 9.4.1.1Mixed Phase II results with Bevirimat
    • 9.5Non-Nucleoside Reverse Transcriptase Inhibitors
      • 9.5.1BILR 355 BS (Boehringer Ingelheim)
      • 9.5.2Calanolide A (Advanced Life Sciences)
      • 9.5.3Etravirine (Johnson & Johnson/[Tibotec])
        • 9.5.3.1Etravirine discontinued in treatment-naïve patients
        • 9.5.3.2Etravirines safety profile
        • 9.5.3.3Ongoing pivotal etravine trials
      • 9.5.4UK-453,061 (Pfizer)
    • 9.6Nucleoside Reverse Transcriptase Inhibitors
      • 9.6.1Alovudine & Fosalvudine (Medivir)
      • 9.6.2Apricitabine (Avexa/Shire Pharmaceuticals)
        • 9.6.2.1Ongoing Pivotal Apricitabine Trials
      • 9.6.3Dexelvutabine (Pharmasset)
      • 9.6.4Elvucitabine (Achillion Pharmaceuticals)
      • 9.6.5Racivir (Pharmasset Inc)
        • 9.6.5.1Racivir’s mutation profile
    • 9.7Protease Inhibitors
      • 9.7.1PPL-100 (Ambrilla Biopharma/Merck & Co.)
    • 9.8NS3 Protease Inhibitors
      • 9.8.1SCH 503034 (Schering-Plough)
        • 9.8.1.1SCH 503034 safety profile
        • 9.8.1.2Ongoing pivotal SCH 503034 trials
      • 9.8.2Telaprevir (Vertex/ Johnson & Johnson/Mitsubishi)
        • 9.8.2.1Telaprevir’s Tolerability Profile
        • 9.8.2.2Ongoing Pivotal Telaprevir Trials
    • 9.9Polymerase Inhibitors
      • 9.9.1R1626 (Roche)
      • 9.9.2R7128 (Roche/[Pharmasset])
      • 9.9.3Valopicitabine (Idenix Pharmaceuticals/Novartis)
      • 9.9.4Valtorcitabine (Index Pharmaceuticals)
    • 9.10Global Sales Forecasts for New Anti-Viral Agents
    • 9.11The Future of the Antiviral Market
  • 10APPENDIX 1 - PHARMACEUTICAL COMPANIES
• Abbott Laboratories
• AstraZeneca AB
• Boehringer Ingelheim Corporation
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc
• Johnson & Johnson,
• Merck & Co Inc
• Novartis International AG
• Pfizer Inc
• Roche
  • 11APPENDIX 2 - BIOTECHNOLOGY AND BIOPHARMACEUTICAL COMPANY PROFILES
    • 11.1Achillon Pharmaceuticals
    • 11.2Agouron Pharmaceuticals (A Pfizer subsidiary)
    • 11.2Genzyme
    • 11.3ISIS Pharmaceuticals
    • 11.4MEDIVIR AB
    • 11.5Panacos
    • 11.6Pharmasset, Inc.
    • 11.7Progenics Pharmaceuticals, Inc.
    • 11.8Tanox
    • 11.9Tibotec
    • 11.10Trimeris, Inc.
    • 11.11Vertex Pharmaceuticals
  • 12APPENDIX 3
    • 12.1Bibliography
• TABLES
• Table 2.1: Infectious Disease Leading Worldwide Health Burden
• Table 3.1: Worldwide Prevalence of HCV
• Table 4.1. Potential for clinical success
• Table 6.1: Historical Sales of 30 Leading Anti-infective Brands US$ million (2001-2005)
• Table 8.1. Infectious Agent Treatment Options
• Table 8.2: Sales Forecasts of Antisense Products US$m 2005A – 2012E
• Table 8.3: Comparison of the Leading DNA Polymerase Inhibitor Brands for the Treatment of CMV
• Table 8.4: Comparison of the Leading DNA Polymerase Inhibitor Brands for the Treatment of HSV
• Table 8.5: Sales Forecasts of DNA Polymerase Inhibitors (US$m) 2005A – 2012E
• Table 8.6: Sales Forecasts of RNA Polymerase Inhibitors 2005A – 2012E
• Table 8.7: Sales Forecasts of Fusion Inhibitors (US$m) 2005A – 2012E
• Table 8.8: Comparison of the Leading Interferon Monotherapies Approved for Hepatitis
• Table 8.9: Comparison of the Leading Interferon Combination Therapies Approved for Hepatitis
• Table 8.10: Sales Forecasts of Interferons (US$m) 2005A – 2012E
• Table 8.11: Sales Forecasts of Monoclonal Antibodies (US$m) 2005A – 2012E
• Table 8.12: Comparison of the Leading NNRTIs
• Table 8.13: Sales Forecasts of NNRTIs (US$m) 2005A – 2012E
• Table 8.14: Comparison of the Leading NRTI Approved for HBV
• Table 8.15: Comparison of the Leading NRTIs Approved for HIV Monotherapy
• Table 8.16: Comparison of the Leading NRTI Combination Therapies Approved for HIV
• Table 8.17: Sales Forecasts of NRTIs (US$m) 2005A – 2012E
• Table 8.18: Comparison of the Leading NtRTIs Brands
• Table 8.19: Sales Forecasts of NtRTIs (US$m) 2005A – 2012E
• Table 8.20: Comparison of the Leading PI Brands – Single Agents
• Table 8.21: The Leading Combination PI Brand
• Table 8.22: Sales Forecasts of PIs (US$m) 2005A – 2012E
• Table 8.23: Leading NIs Approved for Influenza
• Table 8.24: Sales Forecasts of NIs (US$m) 2005A – 2012E
• Table 8.25: Sales Summary of Antiviral Agents (US$m) 2005A – 2012E
• Table 9.1 Reduction of Viral Load Following Treatment with GS 0137
• Table 9.2: Reduction of Viral Load Following Treatment with TNC125
• Table 9.3: Sales Summary of New AntiViral Agents (US$m) 2005A – 2012E
• Table 9.4 Sales Summary of New Antiviral Agents (US$m) 2005A – 2012E
• FIGURES
• Figure 2.1 Schematic of influenza virus
• Figure 3.1 Geographic Distribution of Chronic HBV Infection
• Figure 6.1 Global Anti-Infective Market US$66.5 bn (2006)
• Figure 6.2 Global Anti-Infective Market US$100 bn (2015)
• Figure 6.3 Antiretroviral Agents US$9.7 bn – Drug Class Split (2006)
• Figure 6.4 Hepatitis Antiviral Agents US$3.8 bn – Drug Class Split (2006)
• Figure 6.5 Other Antiviral Agents US$6.4 bn – Therapy Class Split (2006)
• Figure 6.6 The Major Players (2006)
• Figure 6.7 The Major Players (2012)
• Figure 6.8 The Global Antiviral Market (2012)
• Figure 6.9 Antiretroviral Agents US$12.6 bn – Drug Class Split (2012)
• Figure 6.10 Antiviral Agents US$5.5 bn – Drug Class Split (2012)
• Figure 6.11 Other Antiviral Agents US$5.6 bn – Therapy Class Split (2012)
• Figure 7.1 Site of Action of Leading Antiviral Agents
• Figure 8.1 Clinical Efficacy in TORO 1 & 2 Studies
• Figure 8.2 Global HCV Therapy
• Figure 9.1 Structure of Maraviroc
• Figure 9.2 Clinical Efficacy of TNX-355
• Figure 9.3 Virologic Response to TNX-355
• Figure 9.4 Pharmacokinetics of TRI-1144 in Rat Models
• Figure 9.5 Pharmokinetics of TRI-999 formulations in Rat Models
• Figure 9.6 Clinical Efficacy of Vicriviroc
• Figure 9.7 Clinical Efficacy of Vicriviroc in Sub Populations
• Figure 9.8 Clinical Efficacy of MK0518
• Figure 9.9 Schematic of Albuferon’s Structure
• Figure 9.10 Phase II Pharmacokinetic Profile of Albuferon
• Figure 9.11 (+)-Calanolide A Structure
• Figure 9.12 Clinical Efficacy of Racivir
• Figure 9.13 Clinical Efficacy of Racivir
• Figure 9.14 Phase I Clinical Efficacy of Racivir
• Figure 9.15 Clinical Efficacy of Valopicitabine
• Figure 9.16 Clinical Efficacy of Valopicitabine
• Figure 11.1 Medivir AB Pipeline
• Figure 11.2 Pharmassett Pipeline
• Figure 11.3 Progenics Pipeline
• Figure 11.4 Tanox Pipeline
• Figure 11.5 Vertex Pipeline
•  

Other users found this report page using the following search terms: antiviral hcv hiv hbv hepatitis email antivirals market global structure pharma new inhibitor inhibitors pharmaceuticals antiviral email

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.